Cargando…

Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study

BACKGROUND: Studies assessing the effect of suvorexant on delirium prevention included patients treated before development of delirium, which can introduce immortal time bias. The objective of the present study was to evaluate the effect of suvorexant on delirium, comparing patients treated before t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiotsuka, Junji, Uchino, Shigehiko, Sasabuchi, Yusuke, Masuyama, Tomoyuki, Lefor, Alan Kawarai, Sanui, Masamitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714704/
https://www.ncbi.nlm.nih.gov/pubmed/36454811
http://dx.doi.org/10.1371/journal.pone.0277916
_version_ 1784842285565870080
author Shiotsuka, Junji
Uchino, Shigehiko
Sasabuchi, Yusuke
Masuyama, Tomoyuki
Lefor, Alan Kawarai
Sanui, Masamitsu
author_facet Shiotsuka, Junji
Uchino, Shigehiko
Sasabuchi, Yusuke
Masuyama, Tomoyuki
Lefor, Alan Kawarai
Sanui, Masamitsu
author_sort Shiotsuka, Junji
collection PubMed
description BACKGROUND: Studies assessing the effect of suvorexant on delirium prevention included patients treated before development of delirium, which can introduce immortal time bias. The objective of the present study was to evaluate the effect of suvorexant on delirium, comparing patients treated before the onset of delirium with patients treated within 72h of admission using the same dataset. METHODS: Data from adult patients admitted to the ICU from August 2018 to July 2021 were retrospectively analyzed. In “any time before” analysis, the incidence of delirium was compared for patients who received suvorexant at any time during their ICU stay (suvorexant) (unless delirium developed before treatment) with patients who either did not receive suvorexant or received suvorexant after development of delirium (control). This design was used in previously published studies. In “within 72h” analysis, the incidence of delirium was compared for patients who received suvorexant within 72 hours of admission (suvorexant) and patients who did not receive suvorexant or received it more than 72 hours after admission (control). Patients who developed delirium during the initial 72 hours were excluded from “within 72h” analysis (N = 799). RESULTS: “Within 72h” analysis included 1,255 patients, and “any time before” analysis included 2,054 patients (of 6599 admissions). The unadjusted hazard ratio of “any time before” analysis was 0.16 and the 95% confidence interval was 0.13–0.21 (p<0.01). The adjusted hazard ratio was 0.21, and the 95% confidence interval was 0.16–0.27 (p<0.01). “Within 72h” analysis had an unadjusted hazard ratio of 0.54 and the 95% confidence interval was 0.36–0.82 (p<0.01). However, this association lost statistical significance after adjustment for potential confounders (adjusted hazard ratio 1.02, 95% confidence interval 0.65–1.59, p = 0.93). CONCLUSION: Reducing the effect of immortal time bias led to a significantly reduced effect of suvorexant for the prevention of delirium.
format Online
Article
Text
id pubmed-9714704
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-97147042022-12-02 Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study Shiotsuka, Junji Uchino, Shigehiko Sasabuchi, Yusuke Masuyama, Tomoyuki Lefor, Alan Kawarai Sanui, Masamitsu PLoS One Research Article BACKGROUND: Studies assessing the effect of suvorexant on delirium prevention included patients treated before development of delirium, which can introduce immortal time bias. The objective of the present study was to evaluate the effect of suvorexant on delirium, comparing patients treated before the onset of delirium with patients treated within 72h of admission using the same dataset. METHODS: Data from adult patients admitted to the ICU from August 2018 to July 2021 were retrospectively analyzed. In “any time before” analysis, the incidence of delirium was compared for patients who received suvorexant at any time during their ICU stay (suvorexant) (unless delirium developed before treatment) with patients who either did not receive suvorexant or received suvorexant after development of delirium (control). This design was used in previously published studies. In “within 72h” analysis, the incidence of delirium was compared for patients who received suvorexant within 72 hours of admission (suvorexant) and patients who did not receive suvorexant or received it more than 72 hours after admission (control). Patients who developed delirium during the initial 72 hours were excluded from “within 72h” analysis (N = 799). RESULTS: “Within 72h” analysis included 1,255 patients, and “any time before” analysis included 2,054 patients (of 6599 admissions). The unadjusted hazard ratio of “any time before” analysis was 0.16 and the 95% confidence interval was 0.13–0.21 (p<0.01). The adjusted hazard ratio was 0.21, and the 95% confidence interval was 0.16–0.27 (p<0.01). “Within 72h” analysis had an unadjusted hazard ratio of 0.54 and the 95% confidence interval was 0.36–0.82 (p<0.01). However, this association lost statistical significance after adjustment for potential confounders (adjusted hazard ratio 1.02, 95% confidence interval 0.65–1.59, p = 0.93). CONCLUSION: Reducing the effect of immortal time bias led to a significantly reduced effect of suvorexant for the prevention of delirium. Public Library of Science 2022-12-01 /pmc/articles/PMC9714704/ /pubmed/36454811 http://dx.doi.org/10.1371/journal.pone.0277916 Text en © 2022 Shiotsuka et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Shiotsuka, Junji
Uchino, Shigehiko
Sasabuchi, Yusuke
Masuyama, Tomoyuki
Lefor, Alan Kawarai
Sanui, Masamitsu
Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study
title Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study
title_full Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study
title_fullStr Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study
title_full_unstemmed Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study
title_short Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study
title_sort reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: a retrospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714704/
https://www.ncbi.nlm.nih.gov/pubmed/36454811
http://dx.doi.org/10.1371/journal.pone.0277916
work_keys_str_mv AT shiotsukajunji reducingtheeffectofimmortaltimebiasaffectstheanalysisofpreventionofdeliriumbysuvorexantincriticallyillpatientsaretrospectivecohortstudy
AT uchinoshigehiko reducingtheeffectofimmortaltimebiasaffectstheanalysisofpreventionofdeliriumbysuvorexantincriticallyillpatientsaretrospectivecohortstudy
AT sasabuchiyusuke reducingtheeffectofimmortaltimebiasaffectstheanalysisofpreventionofdeliriumbysuvorexantincriticallyillpatientsaretrospectivecohortstudy
AT masuyamatomoyuki reducingtheeffectofimmortaltimebiasaffectstheanalysisofpreventionofdeliriumbysuvorexantincriticallyillpatientsaretrospectivecohortstudy
AT leforalankawarai reducingtheeffectofimmortaltimebiasaffectstheanalysisofpreventionofdeliriumbysuvorexantincriticallyillpatientsaretrospectivecohortstudy
AT sanuimasamitsu reducingtheeffectofimmortaltimebiasaffectstheanalysisofpreventionofdeliriumbysuvorexantincriticallyillpatientsaretrospectivecohortstudy